Clinical trial NCT00232596 - References

Partial-Onset Seizures — Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

Citation(s)

•   JA French, MD; BW Abou-Khalil MD; RF Leroy, MD; EMT Yacubian, MD; P Shin MS,5 S Hall PhD, H Mansbach MD, and V Nohria MD7 on behalf of the RESTORE 1/Study 301 Investigators
  Retigabine Efficacy and Safety Trial for Partial Onset Epilepsy (RESTORE 1): Double-blind, randomized, placebo-controlled trial of retigabine 1200 mg/day as adjunctive therapy in adults with partial-onset seizures. [Neurology].

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients With Partial-Onset Seizures

Details for clinical trial NCT00232596